Search results
Results from the WOW.Com Content Network
NEW YORK (Reuters) -Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did ...
Concerns about protracted legal wrangling and compensation wiped almost $40 billion off the market value of GSK, Sanofi, Pfizer and GSK-spinoff Haleon over roughly a week in August 2022.
The U.S. Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits. GSK settles another Zantac lawsuit in California Skip to ...
Related to courtroom action were offers for a cash advance on impending settlements. Another money matter related to lawsuits and impending settlements is market timing. [24] In June 2023, GSK reached a confidential settlement for one of the lawsuits related to Zantac causing cancer. [25] [26]
The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. ... Pfizer offers up to $250 million to settle Zantac ...
The drugmaker has settled a series of lawsuits related to Zantac over the past 12 months, including several in California. ... GSK does not admit to any liability in either settlement, it said in ...
Sanofi discontinued the ranitidine formulation of Zantac, ... Sanofi to settle 4,000 lawsuits claiming Zantac is linked to cancer. Dan Grossman. ... Those settlements don’t include cases in ...
Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports. May 8, 2024 at 10:28 AM